perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316825;](https://doi.org/10.1101/2024.11.06.24316825) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante





perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316825;](https://doi.org/10.1101/2024.11.06.24316825) this version posted November 11, 2024. The copyright holder for this

- It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .
- $\frac{36}{37}$ <sup> $\dagger$ </sup> These authors contributed equally to this work
- 38
- 39 **Abstract**

40 This study aims to develop new molecular structures as potential therapeutic agents 41 against COVID-19, utilizing both *in silico* and *in vitro* studies. Potential targets of 42 cepharanthine (CEP) against COVID-19 to reveal its underlying mechanism of action 43 were evaluated using *in silico* screening experiments. A library of new molecules was 44 docked into the receptor binding domain of the SARS-CoV-2 spike glycoprotein 45 complex with its receptor, human ACE2, to identify promising compounds. Receptor-46 oriented docking was performed using the most likely macromolecular targets, aimed 47 at inhibiting key viral replication pathways and reducing inflammatory processes in 48 damaged tissues. The hit molecules showed potential inhibition of Mpro and PLpro 49 proteases of SARS-CoV-2, which are involved in viral replication. They also showed 50 a potential inhibitory effect on Janus kinase (Jak3), which mediates intracellular 51 signaling responsible for inflammatory processes.

52 The *in vitro* study examined the effects of the selected hit molecules on the generation 53 of superoxide anions and the release of elastase in activated neutrophils, which are 54 factors that exacerbate tissue inflammation and worsen the clinical manifestations of 55 COVID-19. It was demonstrated that 2-((5-((4-isopropylphenyl)sulfonyl)-6-oxo-1,6- 56 dihydropyrimidin-2-yl)thio)-N-(3-methoxyphenyl)acetamide (**Hit15**) inhibited virus 57 infection by 43.0% at 10  $\mu$ M using pseudovirus assay and suppressed fMLF/CB-58 induced superoxide anion generation and elastase release in human neutrophils with

59 IC<sub>50</sub> values 1.43 and 1.28  $\mu$ M, respectively. **Hit15** showed promising activity against

60 coronavirus that can be further developed into a therapeutic agent.

61 **Keywords:** synthetic compounds, viral entry and replication, spike, SARS-CoV-2, 62 neutrophils

63

# 64 **Introduction**

65 The recent trends in the search for effective drugs against COVID-19 focus on the 66 development of inhibitors of key SARS-CoV-2 proteins. Integrating antiviral and anti-67 inflammatory therapy is a critical approach to managing COVID-19 since the 68 inflammation caused by the immune response leads to serious complications of the 69 disease [1, 2].

70 Understanding the pathological progression and clinical manifestations of COVID-19 71 is a prerequisite for the development of drugs for rational therapeutic intervention. The 72 challenge of developing effective drugs to combat SARS-CoV-2 remains unresolved. 73 There is an urgent need for medications that can suppress the main mechanisms of 74 SARS-CoV-2 replication within the cell and mitigate the consequences of its impact 75 on the human body [3]. This need has become especially relevant with the emergence 76 of new viral variants capable of evading immune protection provided by vaccines [4, 77 5].

78 COVID-19, caused by the SARS-CoV-2 virus, is a complex, multi-organ, and 79 heterogeneous disease. The clinical manifestations of COVID-19 are diverse. The 80 disease can progress from uncomplicated forms to pneumonia and acute respiratory

81 distress syndrome (ARDS), requiring intensive care [6]. The pathogenesis of COVID-82 19 is driven by a hyperactive inflammatory response, leading to severe inflammation 83 and tissue damage, particularly in the lungs [7]. It is known that excessive neutrophil 84 activation causes tissue damage, and the neutrophil activation pathway plays a key role 85 in the poor prognosis of COVID-19 patients by exacerbating lung inflammation and 86 respiratory failure. Activated neutrophils secrete several cytokines, including 87 superoxide anion, which can directly or indirectly cause tissue damage. Neutrophil 88 elastase is a major product secreted by activated neutrophils and a key factor in tissue 89 destruction in inflammatory diseases [8]. The inhibition of superoxide formation and 90 elastase release, which are the markers of the anti-inflammatory response, can reduce 91 the inflammatory burden and limit damage to the lungs and other tissues caused by 92 COVID-19 [9].

93 The integration of antiviral and anti-inflammatory therapies is a key approach to 94 managing COVID-19. This approach was initially utilized, for example, with the 95 introduction of corticosteroids into treatment regimens to reduce the body's 96 inflammatory response [1, 2]. In this context, there is growing interest in biologically 97 active substances from the plant *Jordanian hawksbeard*, as they possess both anti-98 inflammatory and antiviral properties. These substances inhibited the main protease of 99 SARS-CoV-2 and reduced inflammatory processes [8, 10].

100 Studies confirmed the *in vitro* and *in vivo* antiviral potential of cepharanthine (CEP) 101 against SARS-CoV-2. CEP demonstrated multiple molecular mechanisms, including 102 the suppression of the viral entry phase (by interacting with the viral spike protein and

4

103 blocking its binding to ACE2) and reducing the production of inflammatory factors 104 [11, 12].

105 Approaches that enable the targeted creation of new pharmacologically active 106 molecules were implemented in previous studies including computer-aided molecular 107 modeling (CAMM) and QSAR methods [13]. In our search for new agents against 108 SARS-CoV-2, we used workflows that combine several tools, such as pharmacophore 109 screening of large chemical spaces and molecular docking of preselected candidates 110 [14]. 111 In this study, we used *in silico* screening experiments and receptor-oriented docking in

112 the receptor binding domain of the SARS-CoV-2 Omicron spike glycoprotein complex

113 with its receptor, human ACE2. We also used the three-dimensional structural models

114 of other active sites of biological molecules involved in the mechanisms of SARS-

115 CoV-2's impact on the body, using cepharanthine as a representative structure.

116

# 117 **Materials and Methods**

### 118 **Computational Procedures**

119 Molecular ligand analysis and the design of new biologically active molecules were 120 performed using free and publicly available software packages including Jmol [15], 121 PyMol [16], and LigandScout 4.4 [17, 18], which allowed for the pharmacophore 122 analysis and virtual screening of specific molecular databases relative to the generated 123 pharmacophore.

124 LigandScout tools [18] were used to identify the molecular parameters that would 125 correspond to drug-like properties. Molecules with poor permeability and oral 126 absorption (molecular weight  $>$  500, C logP  $>$  5, more than five hydrogen bond donors, 127 and more than ten acceptor groups) were excluded [19]. 128 To understand the possible mechanisms of interaction between substances and

129 biological targets, we used the SwissTargetPrediction web server [20] to predict the

130 biological activity of small molecules. The DataWarrior program was employed to

131 calculate physicochemical properties and analyze molecular scaffolds [21].

# 132 **Preparation of Proteins and Database**

133 X-ray crystal structures of the target proteins were obtained from the Protein Data Bank 134 (PDB) [22] and used for virtual screening and receptor-oriented docking. Molecules 135 with properties matching the pharmacophore structure constituting a set of promising 136 molecules ("hits"), were used in the docking procedure with the active site of the 137 corresponding target protein.

138 For the *in silico* virtual screening, we used a chemical space of molecules containing 139 more than 70,000 organic compounds. The compounds of this database (DB\_KSM) 140 were synthesized by the synthetic group of Prof. S.M. Kovalenko (Department of 141 Organic Chemistry at Kharkiv National University, Ukraine). They included various 142 heterocyclic systems with substituents of different electronic nature, including various 143 aliphatic fragments, amino acid residues, halogens, and others. The representative 144 structure was cepharanthine (CEP), CAS Number 481-49-2 [23].

6

# 145 **Molecular Docking**

- 146 X-ray crystal structures of the corresponding proteins from the Protein Data Bank were
- 147 used for docking. Receptor-oriented docking was performed using the AutoDock Vina

148 program [24].

#### 149 **Chemistry**

150 The synthesis of potentially active hit compounds from virtual screening and docking

151 experiments was carried out using previously developed methods. **Hit2** [25], **Hit3** та

152 **Hit5** [26], **Hit9**, **Hit10** [27], **Hit13** [28], **Hit7**, **Hit15** [29] were prepared (**Fig. 1**).

153

154 **Fig 1**. **Potentially active hits selected as a result of virtual screening and docking** 155

156 All NMR spectra were recorded on a Varian MR-400 spectrometer with standard pulse 157 sequences operating at 400 MHz for <sup>1</sup>H NMR and 101 MHz for <sup>13</sup>C NMR. For all NMR 158 spectra, DMSO-d*6* was used as the solvent. Chemical shift values are referenced to 159 residual protons ( $\delta_H$  2.49 ppm) and carbons ( $\delta_C$  39.6 ppm) of the solvent as an internal 160 standard. LC/MS spectra were recorded on an ELSD Alltech 3300 liquid 161 chromatograph equipped with a UV detector (λ<sub>max</sub> 254 nm), API-150EX mass-162 spectrometer, and using a Zorbax SB-C18 column, Phenomenex (100  $\times$  4 mm) Rapid 163 Resolution HT cartridge  $4.6 \times 30$  mm, 1.8-Micron. Elution started with 0.1 M solution 164 of HCOOH in water and ended with 0.1 M solution of HCOOH in acetonitrile, using a 165 linear gradient at a flow rate of 0.15 mL/min and an analysis cycle time of 25 min.

#### 166 *In vitro* **anti-inflammatory activity in human neutrophils**

167 For the *in vitro* studies, the synthesized compounds (**Fig. 1**) were dissolved in dimethyl 168 sulfoxide (DMSO) to prepare stock solutions. The final concentration of DMSO in cell 169 experiments did not exceed 0.5% and did not affect the measured parameters. Blood 170 was taken from healthy human donors using a protocol approved by the Chang Gung 171 Memorial Hospital review board. Neutrophils were isolated following the standard 172 procedure [30].

173 The inhibition of superoxide anion generation (respiratory burst) was measured based 174 on ferricytochrome *c* reduction as previously described [31]. Briefly, preheated 175 neutrophils (6 × 10<sup>5</sup> cells·mL−1) and 0.6 mg/mL ferricytochrome *c* solution were 176 treated with the tested compounds or DMSO (control) for 5 min. The cells were 177 activated with formyl-methionyl-leucyl-phenylalanine (fMLF, 100 nM)/cytochalasin 178 B (CB, 1 μg/mL) for 13 min. The absorbance was continuously monitored at 550 nm 179 using Hitachi U-3010 spectrophotometer with constant stirring (Hitachi Inc., Tokyo, 180 Japan). Calculations were based on the differences in absorbance with and without 181 superoxide dismutase (SOD, 100 U/mL) divided by the extinction coefficient for the 182 reduction of ferricytochrome  $c$  ( $\varepsilon$  = 21.1/mM/10 mm).

183 Elastase release (i.e., degranulation from azurophilic granules) was evaluated as 184 described before [32]. Briefly, neutrophils were equilibrated with elastase substrate, 185 MeO-Suc-Ala-Ala-Pro-Val-*p*-nitroanilide (100 μM), at 37 °C for 2 min and then 186 incubated with the sample for 5 min. Cells were activated by 100 nM fMLF and 0.5 187 μg/mL CB for 13 min, and changes in the absorbance at 405 nm corresponding to

188 elastase release were continuously monitored. The results were expressed as the 189 percentage of the initial rate of elastase release in the fMLF/CB-activated drug-free 190 control system.

191 **Pseudotyped lentivirus assay**

192 Lentivirus experiments were approved by the Institutional Biosafety Committee 193 of Chang Gung University and performed according to our previous report [42]. Stable 194 hACE-2 overexpressed HEK293T cells were provided by Dr. Rei-Lin Kuo (Chang 195 Gung University) and maintained in DMEM containing 10 % FBS and 10 µg/mL 196 blasticidin. VSV-G pseudotyped lentivirus control (clone name: S3w.Fluc.Ppuro) and 197 SARS-CoV-2 S-protein expressing VSV-G pseudotyped lentiviruses (clone name: 198 nCoV-S-Luc-D614G and nCoV-S-Luc-B.1.617.2) were purchased from RNAi Core 199 Facility of Academia Sinica. hACE-2 overexpressed cells  $(1 \times 10^4 \text{ cells/well})$  were 200 seeded on 96-well plates and incubated at  $37^{\circ}$ C with  $5\%$  CO<sub>2</sub>. Equal relative infection 201 units (RIU)  $(5 \times 10^3 \text{ RU/well} = 0.5 \text{ RIU/cell})$  of pseudotyped lentiviruses were 202 pretreated with various concentrations of antiviral agents in DMEM containing 5% 203 FBS at 37 ℃ for 1 hour. The medium of ACE-2 overexpressed cells was replaced with 204 treated pseudotyped lentivirus and cultured for 24 h. Luciferase activity was measured 205 using a Luciferase Assay System (E2520, Promega) and recorded by a Fluorescence 206 Reader. Cepharanthine served as a positive control.

207 **WST-1 viability assay**

208 The potential cytotoxicity of the tested samples was evaluated by the WST-1 reduction 209 assay in hACE-2-overexpressed HEK293T [40]. The hACE-2-overexpressed 210 HEK293T cells  $(1 \times 10^4 \text{ cells/well})$  were preincubated with DMSO or tested agents for 211 24 h. Then, the WST-1 reagent (M192427, Sigma-Aldrich, MO, USA) was added and 212 incubated for 4 h at  $37 \text{ °C}$ . The absorbance at 405 nm was measured by a Multiska GO 213 spectrophotometer (Thermo Fisher Scientific, MA, USA).

214

#### 215 **Statistical analysis**

216 Results are expressed as mean  $\pm$  S.E.M. of two independent measurements 217 (pseudoviral anti-viral assay) or mean  $\pm$  S.E.M. of three independent measurements 218 (anti-inflammatory assay). The 50% inhibitory concentration  $(IC_{50})$  was calculated 219 from the dose-response curve obtained by plotting the percentage of inhibition versus 220 concentrations (linear function, Microsoft Office, anti-inflammatory assay). Statistical 221 analysis was performed using Student's *t*-test (Sigma Plot, Systat Software, Systat 222 Software Inc., anti-inflammatory). Values with  $*P < 0.05$ ,  $**P < 0.01$ ,  $**P < 0.001$ 223 were considered statistically significant.

- 224
- 225 **Results**

#### 226 *In silico* **models and calculations**

227 Studies of the bis-benzylisoquinoline alkaloid cepharanthine (CEP) against COVID-228 19 identified its significant antiviral and anti-inflammatory potential. However, the

229 precise mechanism of CEP is still under investigation [11, 12]. To model the 230 mechanism of cepharanthine's action on COVID-19, researchers focused on various 231 protein targets available in the Protein Data Bank (PDB). According to scientific 232 literature, one of the primary mechanisms of CEP's action against COVID-19 is its 233 binding to ACE2, which was validated by molecular dynamics (MD) simulations [33]. 234 Cepharanthine was selected as the representative structure to develop new molecules 235 with the potential to inhibit key viral pathways. The 3D crystal structure of the receptor 236 binding domain of the SARS-CoV-2 Omicron variant spike glycoprotein complex with 237 its receptor, human ACE2 (PDB: 7WBP), was chosen as the biological target. 238 We conducted a preliminary pharmacophore screening using the LigandScout suite to 239 identify suitable structures for further investigation. The receptor-binding domain of 240 the SARS-CoV-2 Omicron spike glycoprotein complex with the human ACE2 receptor 241 and the ligand NAG PDB 7WBP [34] was employed as a representative protein-ligand 242 structure for the study (**Fig. 2**).

243

244 **Fig. 2. Receptor binding domain of SARS-CoV-2 Omicron spike glycoprotein**  245 **complex with its receptor human ACE2 with ligand NAG (A), the structure of**  246 **cepharanthine CEP (D) and its pharmacophore (C).**

247

248 The pharmacophore model CEP was used as a search query to identify compounds 249 targeting the binding site of the biological target. Virtual screening (VS) of a molecular 250 database (DB\_KSM) according to the pharmacophore identified in the previous step

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316825;](https://doi.org/10.1101/2024.11.06.24316825) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

251 resulted in identifying several compounds that could be promising in the fight against 252 COVID-19. Based on matching with the pharmacophore, 23 compounds were selected 253 for further study (**Fig. 3**).

254

255 **Fig 3. The structures with possible activity against SARS-COV2 according to VS**  256 **results of DB\_KSM database.**

257









264

265 As shown in **Table 1**, eight compounds (**Hit2**, **Hit3**, **Hit5**, **Hit7**, **Hit9**, **Hit10**, **Hit13**, 266 and **Hit15**) exhibited binding energies exceeding the absolute values of the 267 representative cepharanthine (CEP) structure. These compounds were selected for 268 further molecular docking studies with target proteins identified in the literature as 269 potential pharmacological targets of cepharanthine [33].

270 For the calculations, hub targets for the potential pharmacological mechanism of CEP 271 against COVID-19 were selected (**Table 2**). In the study [33], "network pharmacology" 272 combined with RNA sequencing, molecular docking, and MD modeling was used to 273 identify hub targets and potential pharmacological mechanisms of cepharanthine 274 (CEP) against COVID-19. Nine key hub genes (ACE2, STAT1, SRC, PIK3R1, HIF1A, 275 ESR1, ERBB2, CDC42, and BCL2L1) were identified. Based on these data, we 276 performed docking studies of the home library to the hub targets from the Protein Data 277 Bank [22] described above.

278

# 279 **Table 2. Hub-targets and potential pharmacological mechanisms of action of**

280 **cepharanthine (CEP) against COVID-19** 



perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316825;](https://doi.org/10.1101/2024.11.06.24316825) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .



281

282 Docking was performed using AutoDock Vina with CEP and the studied molecules.

283 The results of molecular docking and binding energies of the molecules are presented

- 284 in **Table 3**.
- 285

#### 286 **Table 3. Molecular docking binding energy results of hub genes with CEP and**

287 **hit-molecules**



It is made available under a CC-DT 4.0 international license.										
1BF5	$-6.0$	$-9.8$	$-9.1$	$-8.7$	$-9.3$	$-8.9$	$-9.0$	$-9.0$	$-8.7$	$-8.9$
1A07	$-7.0$	$-7.4$	$-8.1$	$-7.0$	$-8.3$	$-7.3$	$-8.8$	$-7.2$	$-8.2$	$-7.6$
2IUI	$-6.2$	$-9.5$	$-9.2$	$-9.3$	$-9.8$	$-8.7$	$-9.2$	$-8.9$	$-9.2$	$-8.2$
1H2K	$-4.3$	$-8.8$	$-8.1$	$-9.2$	$-8.4$	$-8.0$	$-8.9$	$-7.9$	$-8.6$	$-8.0$
$2A$ J $F$	$-5.6$	$-11.1$	$-9.7$	$-9.3$	$-9.2$	$-8.8$	$-10.0$	$-8.7$	$-9.6$	$-9.0$
1A52	$-10.4$	$-8.2$	$-9.3$	$-8.4$	$-10.1$	$-8.2$	$-9.2$	$-9.4$	$-9.4$	$-8.7$
2A91	$-6$	$-9.7$	$-9.8$	$-8.4$	$-8.2$	$-8.9$	$-10.0$	$-8.8$	$-8.9$	$-8.2$
<b>7S0Y</b>	$-6.7$	$-8.3$	$-9.4$	$-8.1$	$-8.5$	$-9.5$	$-8.4$	$-9.1$	$-8.7$	$-7.4$
7JGW	$-10.4$	$-8.9$	$-8.9$	$-7.6$	$-8.5$	$-8.2$	$-8.4$	$-9.5$	$-9.2$	$-8.6$

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in

medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316825;](https://doi.org/10.1101/2024.11.06.24316825) this version posted November 11, 2024. The copyright holder for this

288  $a$  Data from [33]

289

290 The molecular docking results showed a good potential for inhibition of Target 2AJF, 291 the spike receptor-binding domain of SARS-CoV-2, in complex with its receptor and

292 a set of targets responsible for modulating the immune response.

293 Additionally, we utilized the SwissTargetPrediction resource further to evaluate the 294 most likely macromolecular targets for CEP (**Fig. 4**) and the new molecules to assess 295 the possibility of using multiple therapeutically relevant targets for the studied 296 compounds, as most bioactive molecules have more than one target [35].

297

298 **Fig 4. The most probable macromolecular targets of CEP, suggested by the**  299 **SwissTargetPrediction resource [20]** 

300

301 The identified biological targets for CEP included the family A G protein-coupled 302 receptors – cell surface proteins that detect molecules outside the cell and activate

303 cellular responses, including immune responses. They also included the 304 electrochemical transporters and ligand-gated ion channels responsible for signal 305 molecule transport regulated by membrane potential or ion flow. The biological targets 306 of the new hit compounds are presented as an aggregate bar chart (**Fig. 5**), reflecting 307 the contribution of each category.

308 **Fig 5. Biological target pool of the new hit molecules proposed by the**  309 **SwissTargetPrediction resource [20]**

310

311 The primary predicted target categories for the new hit molecules, as proposed by the 312 SwissTargetPrediction resource, were the kinase/family A G / B G protein-coupled 313 receptors/protease.

314 **Table 4** presents the categories of biological targets for the new hit molecules: a) 315 Targets responsible for modulating the immune response, which may be one of the 316 mechanisms contributing to tissue inflammation in COVID-19 (kinases 317 (phosphotransferases) / protein-coupled receptor A G /B G family); b) Targets from 318 the protease category, which may be involved in inhibiting key pathways of viral 319 replication.

320

# 321 **Table 4. Categories of biological targets for pharmacological action against**  322 **SARS-COV-2 used in the study**



perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316825;](https://doi.org/10.1101/2024.11.06.24316825) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .



323

324 The results of the molecular docking, the energy characteristics of the binding affinity

325 in kcal/mol (A), and the binding affinity score (BAS) of the studied molecules for the

326 main predicted categories of biological targets are presented in **Table 5**.

327

328 **Table 5. Results of molecular docking: Energy characteristics of binding affinity** 

329 **in kcal/mol (A) and binding affinity score (BAS) of the studied molecules for the** 

330 **main predicted categories of biological targets**



perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316825;](https://doi.org/10.1101/2024.11.06.24316825) this version posted November 11, 2024. The copyright holder for this



It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

331

332 The tested molecules showed potential inhibition of Target 4Z16 (Jak3), a domain of 333 the Janus kinase JAK3, a representative of tyrosine kinases, cytoplasmic enzymes 334 involved in mediating intracellular signaling from cytokine receptors, which are 335 responsible for inflammation processes [36]. Hit molecules also showed potential 336 inhibition of SARS-COV-2 proteases Mpro and PLpro.

337 Several ADME parameters were calculated to evaluate the suitability of the identified 338 compounds in terms of drug-like properties, including chemical absorption, 339 distribution, metabolism, and excretion, which play a crucial role in determining 340 potential drug molecules. **Table 6** presents parameters such as lipophilicity (clogP), 341 topological polar surface area (TPSA), molecular weight (parameter SIZE, g/mol), 342 solubility (LogS), fraction of sp3 carbon atoms (Fraction Csp3), flexibility, and optimal 343 values of these parameters. The studied molecules conform to the drug-likeness 344 properties.

345

#### 346 **Table 6. Drug-likeness properties of selected hits**





perpetuity.

medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316825;](https://doi.org/10.1101/2024.11.06.24316825) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

347

# 348 *In vitro* **models**

#### 349 **SARS-CoV-2 spike/ACE2 pseudovirus neutralization assay**

350 The S-protein and ACE2 receptor play an essential role in the early phases of 351 coronavirus infection [37]. The established binding assay is based on measuring 352 luciferase activity and utilizes stable hACE-2 overexpressed HEK293T cells and 353 SARS-CoV-2 S-protein expressing VSV-G pseudotyped lentiviruses. Omicron 354 B1.1.529 SARS-CoV-2 coronavirus subtype was chosen as the most related subtype to 355 the current variant. It is well known that the mutations increase the infectivity of the 356 COVID-19 virus [38]. The cytotoxicity against hACE2-293T cells was tested, and the 357 results revealed no toxicity (**Table 7**).

358

# 359 **Table 7. Effects of synthetic compounds on hACE-2 overexpressed HEK293T**  360 **viability**



perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316825;](https://doi.org/10.1101/2024.11.06.24316825) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

Hit9	103.83
Hit <sub>3</sub>	95.82
Hit <sub>7</sub>	99.47
Hit10	96.57
Hit <sub>5</sub>	95.19
Hit15	97.33
Hit2	100.00

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

- 361 a Percentage of cell at 10  $\mu$ V(n = 1). Control group (DMSO)
- 362 Next, the SARS-CoV-2 S-protein and ACE2 binding assay results showed activity of

363 **Hit15** with 43.0% inhibition at 10  $\mu$ M (**Table 8**). The compound possesses sulfonyl

364 and pyrimidone moiety that may be responsible for the observed activity [39, 40].

365

- 366 **Table 8. Effect of synthetic compounds in the pseudovirus neutralization assay of**
- 367 **Omicron variants (SARS-CoV-2 Spike protein pseudotyped lentivirus type).**



368 a Percentage of inhibition (Inh.%) at 10  $\mu$ M. Results are presented as mean  $\pm$  S.E.M. (n = 2). Control 369 group (DMSO). SARS-CoV-2 preudovirus strain: Omicron (B.1.1.529).

370

371 In the pseudovirus neutralization assay, cepharanthine showed 97.3% inhibition 372 at 10  $\mu$ M and IC<sub>50</sub> 1.07  $\pm$  0.24  $\mu$ M. The antiviral potential of HIT15 and cepharanthine 373 were in agreement with the reported data [41] . They indicated that both compounds 374 may suppress infection of SARS-CoV-2 pseudovirus in hACE2-overexpressed host 375 cells and may interfere with the S-protein/ACE2 binding. Previous research suggested 376 that reducing the activity of TMPRSS2 using plant secondary metabolites could help 377 manage COVID-19. TMPRSS2 is crucial for the virus entry stage by priming the 378 S-protein of SARS-CoV-2, which facilitates the fusion of viral and host cell 379 membranes. In an *in vitro* molecular docking study, cepharanthine interacted well with 380 the TMPRSS2 and SARS-CoV-2 S-protein [43]. These data bode well with the docking 381 result for cepharantine (**Table 3**) in the SARS-CoV-2 S-protein/ACE2 binding pocket. 382 The anti-inflammatory activity was studied *in vitro* in a model of inhibition of 383 superoxide anion release and elastase in human neutrophils. The effect of new 384 molecules on superoxide anion generation and elastase release in activated human 385 neutrophils was studied (**Table 9**). Superoxide anion generation and elastase release 386 were induced by FMLP/CB and measured respectively. All data are expressed as mean 387  $\pm$  S.E.M. (n = 3–4). \**P* < 0.05, \*\**P* < 0.01, and \*\*\**P* < 0.001 compared with the 388 control.

389

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316825;](https://doi.org/10.1101/2024.11.06.24316825) this version posted November 11, 2024. The copyright holder for this

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

#### 390 **Table 9. Effects of compounds on superoxide anion generation and elastase release**

#### 391 **in fMLF/CB-induced human neutrophils**



Results are presented as mean  $\pm$  S.E.M. (n = 3). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  compared with the control (DMSO).

<sup>a</sup> Concentration necessary for 50% inhibition (IC<sub>50</sub>).

<sup>b</sup> Percentage of inhibition (Inh%) at 100  $\mu$ M. Compounds' solubility was 50 mM.

<sup>c</sup> Percentage of inhibition (Inh%) at 50  $\mu$ M. Compound solubility was 25 mM.

<sup>d</sup> Percentage of inhibition (Inh%) at 10 μM. Compounds' solubility is 5 mM.

e Positive control.

392

393 Experimental results showed that **Hit13**, **Hit9,** and **Hit10** moderately affected elastase

394 release. **Hit15** showed good anti-inflammatory activity with  $IC_{50}$  1.76 and 2.23  $\mu$ M in

395 both superoxide anion generation and elastase release assays in fMLF/CB-induced

396 human neutrophils, respectively. The **Hit15** molecule has good potential for further

397 development to treat COVID-19.

398

# 399 **CONCLUSION**

400 A virtual *in silico* screening and receptor-oriented docking was conducted on three-401 dimensional structural models of active sites in biological molecules involved in the 402 mechanisms of SARS-CoV-2 impact on the body, using cepharanthine as a 403 representative structure. Several hit molecules were identified, characterized by 404 binding energies with the active sites of the targets at levels comparable to or exceeding 405 those of the representative cepharanthine structure. Receptor-oriented docking 406 revealed that these hit molecules have the potential to inhibit SARS-CoV-2 proteases 407 Mpro and PLpro, which play a crucial role in viral replication mechanisms, as well as 408 to inhibit Janus kinase (Jak3), which mediates intracellular signal transduction and is 409 responsible for inflammatory processes.

410 The hit molecules were evaluated *in vitro* for anti-inflammatory activity. They were 411 demonstrated by assessing their inhibitory effects on elastase release in human 412 neutrophils and the generation of superoxide anions, a characteristic of anti-413 inflammatory action. It was shown that the 2-((5-((4-isopropylphenyl)sulfonyl)-6-oxo-414 1,6-dihydropyrimidin-2-yl)thio)-N-(3-methoxyphenyl)acetamide (**Hit15**) exhibited 415 potent anti-inflammatory activity. Several other molecules also demonstrated moderate 416 effects on elastase release.

417

#### 418 **Author Contributions**

419 V.A.G., V.V.I. - Conceptualization,

- 420 Y.-L.C., S.-Y.F., L.V.Y., O.M.K. Data Curation
- 421 V.A.G, O.M.K. Project Administration
- 422 V.V.I., A.B.Z., D.O.A. Software
- 423 O.M.K., T.-L.H. Supervision.
- 424 L.V.Y., V.V.I., S.M.K., M.E.-S., M.K., O.O.M. Writing original draft
- 425 V.A.G. Writing Review & Editing;
- 426 T.-L.H., O.M.K. Funding Acquisition
- 427 All authors have read and agreed to the published version of the manuscript.
- 428

#### 429 **Acknowledgement**

430 VVI, ABZ, SMK, L.V.Y and O.M.K. express their gratitude to the National 431 Research Foundation of Ukraine [\(https://nrfu.org.ua/en/fundraising\\_en/](https://nrfu.org.ua/en/fundraising_en/)) for financial 432 support (grant No. 87/0062 (2021.01/0062) "Molecular design, synthesis and screening 433 of new potential antiviral pharmaceutical ingredients for the treatment of infectious 434 diseases COVID-19"). This research was supported by grants from the National 435 Science and Technology Council [\(https://www.nstc.gov.tw](https://www.nstc.gov.tw/)) (NSTC 113-2321-B-255- 436 001, 113-2321-B-182-003, 112-2321-B-182-003, 112-2321-B-255-001, 111-2320-B-437 255-006-MY3, and 111-2321-B-255-001 granted to T.L.H.; and 113-2320-B-037-023, 438 112-2320-B-037-012, and 111-2320-B-037-007 granted to M.K.), Chang Gung 439 University of Science and Technology [\(https://english.cgust.edu.tw\)](https://english.cgust.edu.tw/) (ZRRPF3L0091 440 and ZRRPF3N0101) granted to T.L.H., Chang Gung Memorial Hospital 441 (<https://www.cgmh.org.tw/eng>) (CMRPF1P0051-3, CMRPF1P0071-3) granted to 442 T.L.H., and Kaohsiung Medical University Research Foundation 443 (<https://www.kmu.edu.tw/index.php/en-gb/research>) (KMU-Q113011) granted to It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316825;](https://doi.org/10.1101/2024.11.06.24316825) this version posted November 11, 2024. The copyright holder for this

444 M.K., Taiwan. We thank Prof. T. Langer for the opportunity to work with the

445 LigandScout suite.

446 The funders had no role in the study design, data collection, analyses, decision

447 to publish, or manuscript preparation.

448

449 **Institutional Review Board Statement**

450 The study was conducted according to the guidelines of the Declaration of Helsinki

451 and approved by the Institutional Review Board of Chang Gung Memorial Hospital

452 (Registration number: IRB No.: 202301906A3C501), 1st August to 30th September

453 2024 was the recruitment period for this study.

454

# 455 **Informed Consent Statement**

456 Informed consent written and signed by donors was obtained from all subjects involved

457 in the study. No minors were included.

458

# 459 **Data Availability Statement**

460 All data are fully available without restriction. All relevant data are within the 461 manuscript.

462

# 463 **Conflicts of Interest**

464 There are no competing interests to declare.

# 466 **References**

- 467 1. World Health Organization. (2020). Corticosteroids for COVID-19. WHO-468 2019-nCoV-Corticosteroids-2020.1-eng.pdf. 469 https://iris.who.int/bitstream/handle/10665/334125/WHO-2019-nCoV-470 Corticosteroids-2020.1-eng.pdf?sequence=1. 471 2. Inpatient Considerations in COVID-19 Treatment and Prevention. *US*  472 *Pharm.* 2022;47(4):HS-1-HS-7. 473 3. Zagaliotis P, Petrou A, Mystridis GA, Geronikaki A, Vizirianakis IS, Walsh TJ. 474 Developing New Treatments for COVID-19 through Dual-Action 475 Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based 476 Pharmacokinetic Modeling. Int J Mol Sci. 2022 Jul 20;23(14):8006. doi: 477 10.3390/ijms23148006. PMID: 35887353; PMCID: PMC9325261. 478 4. Ramesh S, Govindarajulu M, Parise RS, Neel L, Shankar T, Patel S. Emerging 479 SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and 480 Vaccine Efficacy. Vaccines (Basel). 2021 Oct 18;9(10):1195. doi: 481 10.3390/vaccines9101195. PMID: 34696303; PMCID: PMC8537675 482 5. Aleem A, Akbar Samad AB, Vaqar S. Emerging Variants of SARS-CoV-2 and 483 Novel Therapeutics Against Coronavirus (COVID-19). 2023 May 8. In: 484 StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
- 485 PMID: 34033342.
- 486 6. World Health Organization. (2020). Clinical care for severe acute respiratory 487 infection: toolkit: COVID-19 adaptation. World Health Organization.

- 488 https://iris.who.int/bitstream/handle/10665/331736/WHO-2019-nCoV-
- 489 SARI\_toolkit-2020.1-eng.pdf
- 490 7. Rohilla S. Designing therapeutic strategies to combat severe acute respiratory 491 syndrome coronavirus-2 disease: COVID-19. Drug Dev Res*.* 2021;82:12–26
- 492 8. Lai KH, Chen YL, Lin MF, El-Shazly M, Chang YC, Chen PJ. Lonicerae
- 493 Japonicae Flos Attenuates Neutrophilic Inflammation by Inhibiting Oxidative
- 494 Stress. Antioxidants (Basel). 2022 Sep 9;11(9):1781. doi:
- 495 10.3390/antiox11091781. PMID: 36139855; PMCID: PMC9495740
- 496 9. Li J, Zhang K, Zhang, y. *et al.* Neutrophils in COVID-19: recent insights and 497 advances. Virol J **20**, 169 (2023). [https://doi.org/10.1186/s12985-023-02116-](https://doi.org/10.1186/s12985-023-02116-w) 498 [w](https://doi.org/10.1186/s12985-023-02116-w)/
- 499 10.Anti-inflammatory, antiallergic and COVID-19 protease inhibitory activities of
- 500 phytochemicals from the Jordanian hawksbeard: identification, structure–
- 501 activity relationships, molecular modeling and impact on its folk medicinal
- 502 uses. RSC Adv., 2020,10, 38128-38141. 503 https://pubs.rsc.org/en/content/articlelanding/2020/ra/d0ra04876c
- 504 11.Fan H, He ST, Han P, Hong B, Liu K, Li M, Wang S, Tong Y. Cepharanthine: 505 A Promising Old Drug against SARS-CoV-2. Adv Biol (Weinh). 2022 506 Dec;6(12):e2200148. doi: 10.1002/adbi.202200148. Epub 2022 Jul 1. PMID: 507 35775953; PMCID: PMC9350037
- 508 12.Xia B, Zheng L, Li Y, Sun W, Liu Y, Li L, Pang J, Chen J, Li J, Cheng H. The 509 brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods,
- 510 and pharmacokinetics of cepharanthine: a potential small-molecule drug against

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316825;](https://doi.org/10.1101/2024.11.06.24316825) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante



28

- 534 21.DataWarrior. Available from:<https://openmolecules.org/datawarrior/>
- 535 22.Protein Data Bank, Database [Internet]. Available from: [www.rcsb.org](http://www.rcsb.org/)
- 536 23.Cepharanthine. PubChem, Database [Internet]. Available from:
- 537<https://pubchem.ncbi.nlm.nih.gov/compound/10206>
- 538 24.AutoDock Vina. Available from: [https://autodock-](https://autodock-vina.readthedocs.io/en/latest/docking_basic.html)
- 539 [vina.readthedocs.io/en/latest/docking\\_basic.html](https://autodock-vina.readthedocs.io/en/latest/docking_basic.html)
- 540 25.Tkachenko OV, Vlasov SV, Kovalenko SM, Zhuravel IO, Chernykh VP.
- 541 Synthesis and the antimicrobial activity of 1-N-alkylated derivatives of 3-N-
- 542 substituted 1H-thieno[3,2-d]pyrimidine-2,4-diones. Journal of Organic and
- 543 Pharmaceutical Chemistry. 2013, 11(4): 15-21.
- 544 26.Kharchenko YV, Detistov AS, Orlov VD. Polycyclic systems containing 1,2,4-
- 545 oxadiazole ring. 3. 3-(1,2,4-oxadiazol-5-yl)pyridin-2(1H)-ones-synthesis and 546 prediction of biological activity. Visnik Kharkivs'kogo Natsional'nogo
- 547 Universitetu im. V. N. Karazina. 2008; 820: 216-224.
- 548 27.Borisov AV, Detistov OS, Pukhovaya VI, Zhuravel' IO, Kovalenko SM.
- 549 Parallel liquid-phase synthesis of 5-(1H-4-pyrazolyl)-[1,2,4]oxadiazole 550 libraries. J Comb Chem. 2009 Nov-Dec;11(6):1023-9. doi: 551 10.1021/cc900070m. PMID: 19711964.
- 552 28.Konovalova IS, Geleverya AO, Kovalenko SM, Reiss GJ. One-pot synthesis
- 553 and crystal structure of diethyl 2,6-dimethyl-4-(1-(2-nitrophenyl)-1H-1,2,3-
- 554 triazol-4-yl)-1,4-dihydropyridine-3,5-dicarboxylate, C21H23N5O6. Zeitschrift
- 555 für Kristallographie New Crystal Structures. 2023; 2 (238): 381-384.
- 556<https://doi.org/10.1515/ncrs-2022-0573>



- 561 30.Boyum A. Isolation of mononuclear cells and granulocytes from human blood. 562 Isolation of monuclear cells by one centrifugation, and of granulocytes by 563 combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest 564 Suppl. 1968; 97: 77-89.
- 565 31.Korinek M, Hsieh PS, Chen YL, Hsieh PW, Chang SH, Wu YH, Hwang TL.
- 566 Randialic acid B and tomentosolic acid block formyl peptide receptor 1 in 567 human neutrophils and attenuate psoriasis-like inflammation in vivo. Biochem 568 Pharmacol. 2021; 190:114596.
- 569 32.Tsai YF, Chu TC, Chang WY, Wu YC, Chang FR, Yang SC, Wu TY, Hsu YM,
- 570 Chen CY, Chang SH, Hwang TL. 6-Hydroxy-5,7-dimethoxy-flavone 571 suppresses the neutrophil respiratory burst via selective PDE4 inhibition to 572 ameliorate acute lung injury. Free Radic Biol Med. 2017;106: 379-392.
- 573 33.Liu J, Sun T, Liu S, Liu J, Fang S, Tan S, Zeng Y, Zhang B, Li W. Dissecting
- 574 the molecular mechanism of cepharanthine against COVID-19, based on a
- 575 network pharmacology strategy combined with RNA-sequencing analysis,
- 576 molecular docking, and molecular dynamics simulation. Comput Biol Med.
- 577 2022 Dec;151(Pt A):106298. doi: 10.1016/j.compbiomed.2022.106298. Epub
- 578 2022 Nov 11. PMID: 36403355; PMCID: PMC9671524.

- 579 34.PDB 7WBP. Database [Internet]. Available from:
- 580<https://www.rcsb.org/structure/7WBP>
- 581 35.Gfeller D, Michielin O, Zoete V. Shaping the interaction landscape of bioactive
- 582 molecules. Bioinformatics. 2013 Dec 1;29(23):3073-9. doi:
- 583 10.1093/bioinformatics/btt540. Epub 2013 Sep 17. PMID: 24048355.
- 584 36.Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. Janus kinase-targeting therapies
- 585 in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022
- 586 Mar;18(3):133-145. doi: 10.1038/s41584-021-00726-8. Epub 2022 Jan 5.
- 587 PMID: 34987201; PMCID: PMC8730299.
- 588 37.Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S
- 589 et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
- 590 Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr
- 591 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
- 592 PMID: 32142651; PMCID: PMC7102627.
- 593 38.Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-
- 594 CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19
- 595 Virus. *Cell*. 2020/08/20/ 2020;182(4):812-827.e19.
- 596 doi:<https://doi.org/10.1016/j.cell.2020.06.043>
- 597 39.Negi M, Chawla PA, Faruk A, Chawla V. Role of heterocyclic compounds in
- 598 SARS and SARS CoV-2 pandemic. Bioorg Chem. 2020 Nov;104:104315. doi:
- 599 10.1016/j.bioorg.2020.104315. Epub 2020 Sep 24. PMID: 33007742; PMCID:
- 600 PMC7513919.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316825;](https://doi.org/10.1101/2024.11.06.24316825) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante



617



Figure 2









Figure 3





# Figure 5



**Graphical Abstract**